We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
-0.05%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$17.5B
AUM Growth
-$4.53B
Cap. Flow
-$3.73B
Cap. Flow %
-21.26%
Top 10 Hldgs %
49.23%
Holding
203
New
48
Increased
29
Reduced
30
Closed
31

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$292M
2
KKR icon
KKR & Co
KKR
+$280M
3
ROIV icon
Roivant Sciences
ROIV
+$248M
4
MA icon
Mastercard
MA
+$138M
5
TMO icon
Thermo Fisher Scientific
TMO
+$133M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$650M
2
CYBR
CyberArk
CYBR
+$470M
3
CRM icon
Salesforce
CRM
+$334M
4
NDAQ icon
Nasdaq
NDAQ
+$290M
5
RNAM
Avidity Biosciences
RNAM
+$233M

Sector Composition

Rank Sector Weight
1 Healthcare 50.56%
2 Financials 12.21%
3 Technology 11.18%
4 Consumer Discretionary 5.09%
5 Industrials 3.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMER icon
126
Omeros
OMER
$697M
$243K ﹤0.01%
23,000
– –
ALMS
127
Alumis Inc
ALMS
$3.57B
$242K ﹤0.01%
+11,000
New +$275K
APLS
128
DELISTED
Apellis Pharmaceuticals
APLS
$241K ﹤0.01%
+6,000
New +$129K
HQY icon
129
HealthEquity
HQY
$8.27B
$234K ﹤0.01%
2,800
-2,200
-44% -$181K
SNDX icon
130
Syndax Pharmaceuticals
SNDX
$1.98B
$234K ﹤0.01%
10,000
– –
FOLD
131
DELISTED
Amicus Therapeutics
FOLD
$231K ﹤0.01%
16,000
– –
QURE icon
132
uniQure
QURE
$2.73B
$229K ﹤0.01%
14,000
– –
BCRX icon
133
BioCryst Pharmaceuticals
BCRX
$2.32B
$228K ﹤0.01%
24,000
– –
VCYT icon
134
Veracyte
VCYT
$4.57B
$225K ﹤0.01%
7,000
– –
GRFS
135
Grifois
GRFS
$5.18B
$225K ﹤0.01%
28,000
– –
ABVX
136
Abivax
ABVX
$11.5B
$223K ﹤0.01%
2,000
-385,000
-99% -$45.6M
GEHC icon
137
GE HealthCare
GEHC
$28.6B
$214K ﹤0.01%
3,000
– –
RVMDW icon
138
Revolution Medicines Inc Warrant
RVMDW
$95.1M
$209K ﹤0.01%
120,085
– –
HIMS icon
139
Hims & Hers Health
HIMS
$7.57B
$208K ﹤0.01%
10,000
-3,376,986
-100% -$79.8M
BLTE
140
Belite Bio
BLTE
$6.13B
$207K ﹤0.01%
+1,300
New +$219K
MMSI icon
141
Merit Medical Systems
MMSI
$4.48B
$207K ﹤0.01%
3,000
– –
SUPN icon
142
Supernus Pharmaceuticals
SUPN
$2.75B
$207K ﹤0.01%
+4,000
New +$204K
HR icon
143
Healthcare Realty
HR
$7.36B
$204K ﹤0.01%
12,000
– –
URGN icon
144
UroGen Pharma
URGN
$2B
$198K ﹤0.01%
11,000
– –
VIR icon
145
Vir Biotechnology
VIR
$1.56B
$197K ﹤0.01%
+22,000
New +$175K
PGEN icon
146
Precigen
PGEN
$1.81B
$194K ﹤0.01%
50,000
– –
SDGR icon
147
Schrodinger
SDGR
$1.12B
$193K ﹤0.01%
17,000
-54,000
-76% -$746K
DYN icon
148
Dyne Therapeutics
DYN
$3.88B
$181K ﹤0.01%
10,000
– –
NVAX icon
149
Novavax
NVAX
$1.3B
$179K ﹤0.01%
22,000
-173,000
-89% -$1.57M
PACB icon
150
Pacific Biosciences
PACB
$422M
$178K ﹤0.01%
135,000
– –
4 5
6
7 8

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Farallon Capital Management held 203 positions worth $17.5B, down 21% from $22.1B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Farallon Capital Management withdrew a net $3.73B in Q1 2026, closing 31 positions and reducing 30 holdings. Its most notable exit was Exact Sciences, an estimated $650M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 43% a quarter earlier, followed by Financials and Technology.

Against the trend, Farallon Capital Management opened a new position in Dianthus Therapeutics worth $70.2M.

  • Farallon Capital Management's largest Q1 2026 buy was Dianthus Therapeutics: 836,000 shares worth $70.2M.
  • Farallon Capital Management added most to Broadcom in Q1 2026, an estimated $292M increase.
  • Farallon Capital Management's biggest Q1 2026 reduction was Wabtec, cutting an estimated $210M.
  • Farallon Capital Management fully exited Exact Sciences in Q1 2026, selling an estimated $650M.
  • Farallon Capital Management's ten largest holdings make up 49% of its $17.5B portfolio in Q1 2026.
  • Farallon Capital Management opened 48 new positions and closed 31 in Q1 2026.
  • Farallon Capital Management's portfolio value fell 21% quarter-over-quarter to $17.5B.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.